Sandra Schaftner volunteers for the German Lupus Group, Lupus Erythematodes Selbsthilfegemeinschaft e.V.. She is also one of the German-version translation volunteers of Lupus100. Lupus100.org is a MULTILINGUAL website run by Lupus Europe that contains clear answers to 100 questions about lupus. Lupus experts and patients have worked collaboratively on the website. Lupus100.org has also been endorsed by ERN ReCONNET SLE Working Group doctors. Below is a piece Sandra wrote on the need for Lupus100, the translation validation process and some wonderful feedback on the website! 

 

New website answers 100 questions about lupus

 

When we have questions about our disease, we lupus sufferers are often advised: “Don’t Google!” Rightly so, because there is a lot of outdated and sometimes completely wrong information on the internet. There are also some scientific websites that provide correct information. But these are difficult to understand because the texts are full of technical terms. Lupus Europe has wanted to solve this problem for many years and now the project has finally been realised. Lupus Europe has launched Lupus100 (www.lupus100.org). Lupus100 answers 100 important questions about lupus in now thirteen languages (including German). More languages are to be added by the end of the year.

 

How the Lupus100 website was created

 

I was involved in the creation of the German site and would like to give you a little insight into how the website came about. The project is based on a French book called “Lupus in 100 Questions”. This book has been around for many years and is very popular in France. An English version was first created from the book, for which members of the Lupus Europe Patient Advisory Network (PAN) worked together with doctors specialising in lupus. A number of France-specific questions were removed and replaced with internationally relevant questions, suggested by PAN members and answered together with the lupus experts.

All 100 questions and answers in the English version were reviewed and feedback incorporated by doctors from the Lupus Working Group of the European Reference Network for Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET) and lupus patients from the Lupus Europe PAN network. Lupus Europe translated the resulting English version into many different languages, including German, using an automated translation tool called Deepl Pro. For each language, they created a Word document containing the original English text and the European language draft machine translation side by side. This text was then sent to volunteer lupus patients and lupologists from each country, who corrected the automatic translation.

 

This is where my task began. I had agreed to review the German translation from the patient’s point of view. The suggestion from Lupus Europe was that first the people with lupus and then the doctors improve the texts. So directly after an online meeting in autumn 2022, where we were given background information and a short manual, I sat down to check the approximately 170 Word pages. The automatic translation was surprisingly good because the Pro version was used instead of the normal Deepl. Nevertheless, there was still a lot to be improved. Sometimes the wording sounded bumpy, sometimes the words were translated so inappropriately that a completely different meaning emerged in the German sentence.

 

When I had finished after a few weeks, I sent the document with my comments to three doctors from the University Hospital in Düsseldorf: Dr Chehab, Dr Düsing and Dr Mucke. They divided the document into three parts and also added their improvements. After a few arrangements, we sent the finished document back to Lupus Europe at the end of 2022, who were very grateful for our work. During the spring, the 100 German questions and answers were put on the website and we were able to finalise the online version. The public announcement of the multilingual website www.lupus100.org took place on World Lupus Day on 10 May. For me it was a great moment to see this joint project of so many volunteers from all over Europe online.

 

Good feedback for Lupus100

 

The website has since received a lot of praise. Jeanette Andersen, Chair of Lupus Europe, added that not only sufferers but also doctors find the website useful. Personally, I also find the selection of questions very successful. Many are very practical and I have learned a lot. For example, I didn’t know why people with lupus shouldn’t take ibuprofen. The answer is under the question “What drugs should be avoided in lupus?” and is: “A non-steroidal anti-inflammatory drug (NSAID) called ibuprofen can sometimes cause severe headaches very quickly and sometimes even “chemical” meningitis (without microbes), especially in lupus patients. This drug, which is available over the counter, is therefore contraindicated in your case.”

Also, I thought until now that lupus sufferers would notice it after a few days at the latest if they got too much sun. But under the question “Can I sunbathe with lupus?” I surprisingly read: “Sun exposure can also cause a relapse of the disease and the appearance of other symptoms such as joint complaints, tiredness and possibly more severe damage. These symptoms often occur several weeks or even months after sun exposure. Lupus flare-ups are therefore more common in autumn and early winter. The time lag between sun exposure and the onset of the lupus flare explains why the patient often sees no connection between these two manifestations.”

I am sure that the vast majority of lupus sufferers can still discover surprising new information at www.lupus100.org. And the great thing is: we don’t have to question the credibility of the website, but can be sure that the texts have been checked by several lupus experts.

Text by Sandra Schaftner


And the original piece Sandra wrote in German: 

 

Neue Internetseite beantwortet 100 Fragen über Lupus

Wenn wir Fragen zu unserer Krankheit haben, wird uns Lupus-Erkrankten häufig geraten: „Nicht googeln!“ Zurecht, denn im Internet finden sich viel e veraltete und teils auch komplett falsche Informationen. Es gibt auch einige wissenschaftliche Internetseiten, die richtige Informationen liefern. Diese sind aber schwierig zu verstehen, weil die Texte voller Fachwörter sind.

 

Dieses Problem wollte die europäische Lupus-Dachorganisation Lupus Europe seit vielen Jahren lösen und nun konnte das Projekt endlich umgesetzt werden. Lupus Europe hat die Internetseite www.lupus100.org ins Leben gerufen, die 100 wichtige Fragen über Lupus in mittlerweile zwölf Sprachen (auch auf Deutsch) beantwortet. Bis Jahresende sollen noch mehr Sprachen hinzukommen.

 

So entstand die Internetseite

 

Ich war bei der Erstellung der deutschen Seite beteiligt und möchte euch hier einen kleinen Einblick geben, wie die Internetseite entstand. Sie basiert auf einem französischen Buch, das „Lupus in 100 Fragen“ heißt. Dieses gibt es schon seit vielen Jahren und es ist in Frankreich sehr beliebt. Aus dem Buch wurde zunächst eine englische Version erstellt, wofür Mitglieder einer Lupus-Europe-Gruppe namens Patient Advisory Network (PAN) mit auf Lupus spezialisierten Ärztinnen und Ärzten zusammenarbeiteten. Einige Frankreich-spezifische Fragen wurden entfernt und durch international relevante Fragen ersetzt, die PAN-Mitglieder vorschlugen und gemeinsam mit den Lupus-Experten beantworteten.

 

Alle 100 Fragen und Antworten der englischen Version wurden von Ärztinnen und Ärzten aus der Lupus-Arbeitsgruppe des Europäischen Referenznetzwerks für Bindegewebs- und muskuloskelettale Erkrankungen (ERN ReCONNET) und Lupus-Erkrankten aus dem PAN-Netzwerk geprüft und deren Feedback eingearbeitet. Die daraus entstandene englische Version übersetzte Lupus Europe mit einem automatischen Übersetzungstool namens Deepl Pro in viele verschiedene Sprachen, unter anderem auch ins Deutsche. Für jede Sprache erstellten sie ein Word-Dokument, das nebeneinander den englischen Originaltext und die deutsche Maschinenübersetzung enthielt, und schickten es an freiwillige Lupus-Erkrankte und Ärztinnen und Ärzte aus den jeweiligen Ländern, die die automatische Übersetzung korrigierten.

 

An dieser Stelle begann meine Aufgabe. Ich hatte mich bereiterklärt, die deutsche Übersetzung aus Patientensicht zu überprüfen. Der Vorschlag von Lupus Europe war, dass zuerst die Lupus-Erkrankten und anschließend die Ärztinnen und Ärzte die Texte verbessern. Also setzte ich mich direkt nach einem Online-Treffen im Herbst 2022, bei dem wir Hintergrundinformationen und eine kurze Anleitung bekamen, an die circa 170 Word-Seiten, die es zu prüfen galt. Die automatische Übersetzung war erstaunlich gut, weil nicht das normale Deepl, sondern die Pro-Version verwendet wurde. Trotzdem gab es noch viel auszubessern. Mal hörte sich die Formulierung holprig an, mal waren die Wörter so unpassend übersetzt, dass sich im deutschen Satz ein ganz anderer Sinn ergab.

 

Als ich nach ein paar Wochen damit fertig war, schickte ich das Dokument mit meinen Anmerkungen an drei Ärztinnen und Ärzte vom Uniklinikum Düsseldorf, Dr. Chehab, Dr. Düsing und Dr. Mucke. Sie teilten das Dokument in drei Teile und fügten ebenfalls ihre Verbesserungen hinzu. Nach ein paar Absprachen schickten wir das fertige Dokument Ende 2022 zurück an Lupus Europe, die sich sehr für unsere Arbeit bedankten. Im Laufe des Frühlings wurden die 100 deutschen Fragen und Antworten auf die Internetseite gestellt und wir konnten die Onlineversion final prüfen. Die öffentliche Ankündigung der mehrsprachigen Internetseite www.lupus100.org fand zum Welt-Lupus-Tag am 10. Mai statt. Für mich war es ein toller Moment, dieses Gemeinschaftsprojekt so vieler Freiwilliger aus ganz Europa online zu sehen.

 

Gutes Feedback für Lupus100

 

Die Internetseite erhielt seitdem viel Lob. Jeanette Andersen, die Vorsitzende von Lupus Europe, ergänzte, dass nicht nur Erkrankte, sondern auch Ärztinnen und Ärzte die Internetseite nützlich finden. Ich persönlich finde vor allem auch die Auswahl der Fragen sehr gelungen. Viele sind sehr praxisnah und ich habe Einiges dazugelernt. Beispielsweise wusste ich bisher nicht, warum Lupus-Erkrankte kein Ibuprofen nehmen sollten. Die Antwort darauf steht unter der Frage „Welche Medikamente sollten bei Lupus vermieden werden?“ und lautet: „Ein nichtsteroidales Antirheumatikum (NSAR) namens Ibuprofen kann manchmal sehr schnell starke Kopfschmerzen und manchmal sogar eine “chemische” Meningitis (ohne Mikroben) auslösen, insbesondere bei Lupuspatienten. Dieses Medikament, das rezeptfrei erhältlich ist, ist daher in Ihrem Fall kontraindiziert.“

 

Außerdem dachte ich bisher, dass Lupus-Erkrankte es spätestens nach ein paar Tagen bemerken, wenn sie zu viel Sonne abbekommen haben. Doch unter der Frage „Kann ich mit Lupus ein Sonnenbad nehmen?“ las ich überraschenderweise: „Sonneneinstrahlung kann auch einen Rückfall der Krankheit und das Auftreten anderer Symptome wie Gelenkbeschwerden, Müdigkeit und möglicherweise schwerere Schäden verursachen. Diese Erscheinungen treten oft erst mehrere Wochen oder sogar Monate nach der Sonnenexposition auf. Lupusschübe treten daher häufiger im Herbst und frühen Winter auf. Der zeitliche Abstand zwischen der Sonnenexposition und dem Ausbruch des Lupusschubs erklärt, warum der Patient oft keinen Zusammenhang zwischen diesen beiden Erscheinungen sieht.“

 

Ich bin mir sicher, dass die allermeisten Lupus-Erkrankten noch überraschende neue Informationen bei www.lupus100.org entdecken können. Und das Tolle ist: Wir müssen die Glaubwürdigkeit der Internetseite nicht hinterfragen, sondern können uns sicher sein, dass die Texte von mehreren Lupus-Experten überprüft wurden.

 

Text von Sandra Schaftner

 

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons

💜 We've taken part in the EULAR PARE Conference 2026 in Brussels! And what an interesting opportunity to discuss the future of AI in healthcare!

🌍 Bringing together more than 100 delegates and speakers from across Europe and beyond, the conference explored some of the most important questions surrounding artificial intelligence in rheumatology and patient advocacy.

From the opportunities and risks of AI to health inequalities, accessibility and European health policy, the discussions highlighted why patient perspectives must be part of the conversation.

🤩 We were particularly proud to see Jeanette Andersen, Chair of the Lupus Europe Board, sharing our experience with #LupusGPT in her presentation, “AI as a Partner in Care: Empowering the RMD Community with Information”.

💡 Jeanette explained how #LupusGPT was developed with patients and clinicians to offer free, multilingual access to reliable lupus information based on validated sources.

She also introduced #EasyLupus, which provides the same trusted information in simpler language, highlighting why accessibility must be considered when developing AI tools.

But one of the most important messages from her presentation went beyond technology.

💜 Patient organisations have much more to contribute to AI than simply using tools developed by others.

As Jeanette highlighted, patient organisations bring lived experience, knowledge of unmet needs, trusted information and an understanding of the barriers people face when accessing health information.

Technology alone cannot tell us what patients really need or what makes a tool genuinely useful.

Patients and patient organisations should not simply be users of AI. They should help shape its development.

👏 A big thank you to EULAR PARE for bringing together so many different perspectives and creating space for meaningful discussions about the future of healthcare and patient involvement!
...

💜 Weve taken part

🦋 One of the greatest strengths of patient organisations is the support, understanding and sense of community they offer to people living with lupus. 💜

🇧🇬 A great example comes from Организация на пациентите с ревматологични заболявания, who shared their psychological support initiative at the #LupusConvention!

💜 Launched in December 2025, this pilot project provides a safe and supportive space where participants can share their experiences and discuss the challenges of living with lupus, from fatigue and anxiety to relationships and everyday life.

👥 Led by a clinical psychologist, the group currently brings together six women. The project is expected to run until December 2026, while the organisation explores funding opportunities to continue and expand the initiative.

Thank you to our Bulgarian colleagues for sharing their experience, and congratulations on the amazing job you are doing! ❤️

🌍 This is just one example of the valuable work patient organisations are doing across Europe, often responding to needs that go beyond medical care. We'll share more in the coming days!

💜 Are you living with lupus? You don't have to navigate everything alone! Your national lupus organisation may offer information, support, activities and opportunities to connect with others who understand your experiences.

🔗 Find your national lupus organisation and get in touch:
lupus-europe.org/lupus-members/
...

Image attachment
Image attachment

💜 Young people living with lupus are not only the future of patient advocacy. Their voices matter today!

On 23 and 24 October, LUPUS EUROPE was delighted to be represented at the first 𝗘𝗣𝗙 𝗬𝗼𝘂𝘁𝗵 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝟮𝟬𝟮𝟲 in Brussels by Ana Rita Vieira, from the LUPUS EUROPE Youth Group, and Lena Koskina, LUPUS EUROPE's Youth Group Coordinator.

🌍 Organised by European Patients' Forum and its EPF Youth Group, the Congress brought together young patient advocates from across Europe to explore the challenges facing young people living with chronic conditions, from economic uncertainty and climate change to the barriers they encounter when trying to influence healthcare decisions.

🌟 One particularly important question ran through the discussions: 𝗵𝗼𝘄 𝗱𝗼 𝘄𝗲 𝗺𝗼𝘃𝗲 𝗯𝗲𝘆𝗼𝗻𝗱 𝘀𝗶𝗺𝗽𝗹𝘆 𝗴𝗶𝘃𝗶𝗻𝗴 𝘆𝗼𝘂𝗻𝗴 𝗽𝗲𝗼𝗽𝗹𝗲 𝗮 𝘀𝗲𝗮𝘁 𝗮𝘁 𝘁𝗵𝗲 𝘁𝗮𝗯𝗹𝗲, 𝗮𝗻𝗱 𝗲𝗻𝘀𝘂𝗿𝗲 𝘁𝗵𝗲𝘆 𝗵𝗮𝘃𝗲 𝗮 𝗿𝗲𝗮𝗹 𝘀𝗮𝘆 𝗶𝗻 𝘁𝗵𝗲 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝗯𝗲𝗶𝗻𝗴 𝗺𝗮𝗱𝗲❓

The conversations also highlighted something easily overlooked: 𝗺𝗲𝗮𝗻𝗶𝗻𝗴𝗳𝘂𝗹 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗶𝗼𝗻 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝘀 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝗮𝗻 𝗶𝗻𝘃𝗶𝘁𝗮𝘁𝗶𝗼𝗻. Young people living with chronic conditions are often balancing their health with education, employment and financial pressures. Advocacy opportunities need to recognise those realities, and not be accessible only to those who can afford the time and resources to participate.

🦋 At LUPUS EUROPE, supporting the Youth Group means actively helping create those opportunities, connecting young advocates with others across Europe and ensuring their perspectives can meaningfully contribute to the work we do.

Young people living with lupus are already advocates, bringing their experiences, ideas and knowledge into conversations that matter.

💜 Thank you to European Patients' Forum and its EPF Youth Group for bringing everyone together, and to Rita and Lena for representing LUPUS EUROPE at this important Congress!
...

💜 Young people li

🔊 Hot off the press!

💜 Treatment adherence is important, complex and multifactorial.

But understanding the importance of treatment adherence is not the same as knowing how to support it in everyday clinical practice.

That’s why, in 2020, EULAR published its Points to Consider for the prevention, screening, assessment and management of nonadherence to treatment in people with rheumatic and musculoskeletal diseases.

But having recommendations is only the first step. How can we ensure they become part of everyday clinical practice?

🤩 An interesting new viewpoint published in EULAR Rheumatology Open, co-authored by Jeanette Andersen, Chair of the Lupus Europe Board, now explores the challenges of putting these recommendations into routine rheumatology care.

The article highlights that nonadherence is not simply a matter of individual patient behaviour. Concerns about treatment, practical difficulties, access to medication, socioeconomic circumstances and communication with healthcare professionals can all play a role.

The authors highlight five key priorities for putting adherence support into routine rheumatology practice:

🔹 Assessment: Identifying adherence behaviours and the barriers behind them.
🔹 Monitoring: Reassessing adherence over time, as it may change throughout the disease course.
🔹 Shared decision-making: Discussing patients’ preferences, expectations and concerns through non-judgemental communication.
🔹 Multidisciplinary care: Involving the wider healthcare team according to individual needs.
🔹 Training: Making adherence support part of rheumatology education and professional development.

💜 The challenge is not the lack of recommendations, but making adherence assessment and support a routine part of rheumatology care.

📖 Read the open-access viewpoint: doi.org/10.1016/j.ero.2026.100261
...

Image attachment
Image attachment
Image attachment
Image attachment
LUPUS EUROPE Uniting people with Lupus throughout Europe
Send